Doxazosin increases low density lipoprotein receptor activity.
The effect of the alpha 1 adrenoreceptor antagonist doxazosin on low density lipoprotein (LDL) receptor activity, has been studied in cultured skin fibroblasts. Doxazosin at a concentration of 10(-5) M significantly increased the LDL receptor activity. The possible clinical implications of this observation are discussed.